Kirsten Ritstier-Ruigrok
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.
Journal: Nature medicine
Published: February 24, 2025
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
Journal: Cancers
Published: November 24, 2023
Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Journal: Breast cancer research : BCR
Published: March 13, 2023
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
Journal: BMC cancer
Published: November 24, 2021
Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 16, 2021
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Journal: Endocrine-related cancer
Published: March 01, 2019
Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Journal: Molecular oncology
Published: January 27, 2015
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Journal: PloS one
Published: November 15, 2013
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Journal: Breast cancer research and treatment
Published: February 22, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026